PixarBio, a Medford, Massachussetts-headquartered specialty pharmaceutical and biotechnology company focused on preclinical and clinical commercial development of neurological drug-delivery systems for post-operative pain, has partnered with Particle Sciences, a Lubrizol Company, under which Particle Sciences will provide cGMP manufacture for clinical trials of PixarBio’s NeuroRelease NR14, a 14-day post-surgical pain treatment.

PixarBio says it plans to apply in 2018 to the US Food and Drug Administration for fast-track approval through the Center for Drug Evaluation and Research’s (CDER) breakthrough therapy designation.

Source: PixarBio